Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of “Hold” by Analysts

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has received a consensus rating of “Hold” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $8.24.

A number of equities analysts recently issued reports on the company. UBS Group lowered their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. HC Wainwright dropped their target price on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 29th. Wedbush restated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Wells Fargo & Company decreased their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Finally, Guggenheim decreased their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th.

Insider Buying and Selling

In other news, Director Jan Skvarka acquired 60,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the acquisition, the director now owns 149,551 shares in the company, valued at $257,227.72. This trade represents a 67.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 3.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Erste Asset Management GmbH acquired a new position in Zentalis Pharmaceuticals during the third quarter worth $37,000. Paloma Partners Management Co purchased a new position in Zentalis Pharmaceuticals during the 3rd quarter valued at about $37,000. Aigen Investment Management LP purchased a new position in Zentalis Pharmaceuticals during the 3rd quarter valued at about $41,000. Prudential Financial Inc. purchased a new position in Zentalis Pharmaceuticals during the 4th quarter valued at about $39,000. Finally, Capstone Investment Advisors LLC purchased a new position in Zentalis Pharmaceuticals during the 3rd quarter valued at about $48,000.

Zentalis Pharmaceuticals Trading Up 1.0 %

ZNTL stock opened at $2.08 on Wednesday. The company’s 50 day moving average is $2.72 and its two-hundred day moving average is $3.15. The stock has a market cap of $148.22 million, a P/E ratio of -0.84 and a beta of 1.81. Zentalis Pharmaceuticals has a twelve month low of $1.61 and a twelve month high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.36. On average, equities research analysts predict that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.